Postoperative Pain Management on Patients Undergoing Lung Tumor Resection

China Medical University

Status: Not yet enrolling

Conditions: Postoperative Pain; Lung Tumor; Lung Cancer

Treatments: Drug: Dinalbuphine sebacate; Drug: Analgesic injectables; Drug: Enteral analgesics

Study type: Observational

Funder types: Other

Identifiers

NCT06397807

CMUH-112-01

Details and patient eligibility

About

Multimodal analgesia (MMA) is an essential part of Enhanced Recovery After Surgery (ERAS) protocol. The principle of MMA is to manage pain with analgesics of multiple classes acting on distinct target sites through different strategies. MMA can reduce the adverse reaction caused by opioids and improve the quality of recovery from surgery. Inadequate postoperative pain management will increase the risk of complications, including pneumonia, deep vein thrombosis, infection, delayed surgical healing, and chronic postoperative pain.

Full description

This prospective, observational study is planned to investigate the efficacy of different MMA regimens conducting in our hospital. Patients undergoing video-assisted thoracoscopic (VATS) lung tumor resection will be invited to participate in the study and grouped based on the MMA regimens. Anxiety, quality of recovery, pain intensity will be evaluated pre- and post-operatively. Demographic data, surgery record, medicine record and postoperative complications will be gained from medical history system and analyzed.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. aged above 18.
2. diagnosed as lung cancer.
3. planning to undergo primary, video-assisted thoracoscopic lung tumor resection.
4. American Society of Anesthesiology Physical Class 1~3.

Exclusion criteria

1. unable to take assessments of the endpoints.
2. having this surgery in an emergency.
3. surgery involving other orangs, such as esophagus and stomach.
4. severe abnormality of cardiac, hepatic, or renal function.
5. allergic to opioids.
6. allergic to NSAIDs.
7. diagnosed as chronic pain or chronic use of analgesics.
8. unsuitable for participation judged by investigator.

Trial design

400 participants in 2 patient groups

NALDEBAIN

Description:

Patients injected with dinalbuphine sebacate intramuscularly will be allocated to NALDEBAIN group.

Treatment:

Drug: Enteral analgesics

Drug: Analgesic injectables

Drug: Dinalbuphine sebacate

CONTROL

Description:

Patients receiving postoperative pain management without dinalbuphine sebacate will be allocated to CONTROL group.

Treatment:

Drug: Enteral analgesics

Drug: Analgesic injectables